- Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) Eli Lilly and Company
- At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma Yahoo Finance
- U.S….
Category: 6. Business
-
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) – Eli Lilly and Company
-
Assessing Valuation After Steady Earnings Growth and Weak One-Year Share Price Returns
Kenvue (KVUE) keeps drifting lower even after reporting steady revenue and profit growth, which raises a simple question for investors: is the market underpricing a slow but dependable consumer health story?
See our latest analysis for…
Continue Reading
-
Former Federal Reserve Bank Executive Reveals The $1 Trick That Turns ‘Someday’ Investors Into ‘Today’ Investors
One dollar is all it takes to transform someone from a perpetual “someday” investor into an actual market participant, according to a former Federal Reserve Bank of Boston executive who spent years inside America’s most powerful…
Continue Reading
-
Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML
The all-oral combination comprised of revumenib (Revuforj) plus decitabine/cedazuridine and venetoclax (Venclexta; SAVE regimen) elicited responses in patients with newly diagnosed acute myeloid leukemia (AML) although a concern for…
Continue Reading
-
Exploring 3 High Growth Tech Stocks in Australia
As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact…
Continue Reading
-
Ted Sarandos Spoke With Donald Trump Ahead of Warner Bros. Deal
Netflix taking pole position to win the race for Warner Bros. Discovery sent shockwaves through Hollywood, partially because it was presumed that Paramount Skydance CEO David Ellison had the support of President Donald Trump.
Now multiple…
Continue Reading
-
Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV – Medscape
- Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV Medscape
- 52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV AJMC
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response…
Continue Reading
-
Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML
Treatment with oral decitabine/cedazuridine (Inqovi) plus venetoclax (Venclexta) demonstrated high response activity and encouraging survival outcomes in patients with treatment-naive high-risk myelodysplastic syndromes (HR-MDS) or chronic…
Continue Reading
-
Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM
The all-antibody–based doublet comprising teclistamab-cqyv (Tecvayli) and daratumumab (Darzalex) produced deep responses, high minimal residual disease (MRD) negativity rates, and was well-tolerated when administered as frontline treatment to…
Continue Reading
-
Linklaters leads on Unilever’s demerger of The Magnum Ice Cream Company and its stock exchange listings in Amsterdam, London and New York
Linklaters has advised Unilever PLC (Unilever) and The Magnum Ice Cream Company N.V. (TMICC) on the creation of TMICC, its separation and demerger from Unilever and its listings on the Amsterdam, London and New York stock exchanges.
In one…
Continue Reading